Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by PDMitchellon Jan 21, 2014 6:42am
339 Views
Post# 22114286

Mallinckrodt’s new drug should generate ‘tens of millions’

Mallinckrodt’s new drug should generate ‘tens of millions’ But Xartemis is expected to generate “hundreds of millions in revenue,”

Does this suggest a potential conflict of interest or simply a realization that Pennsaid is not as effective or convenient as we've thought?

 

"Although Trudeau said Pennsaid will be a valuable product for generating revenue, he said it won’t make as big of a splash as other drugs in the pipeline such as Xartemis XR, a 12-hour extended-release painkiller that is a combination of oxycodone and acetaminophen. Xartemis is currently awaiting FDA approval.

Xartemis is expected to generate “hundreds of millions in revenue,” Trudeau said. Plus, the product addresses acute pain, an area that yields about 200 million prescriptions annually in the U.S,   million of which fall in Xartemis’ target market, according to Mallinckrodt."

Bullboard Posts